Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness
Reaching Protein Target With SmofKabiven® Extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute Critical Illness
Sponsor: Fresenius Kabi
Terminated
Study had to be put on hold after the outbreak of Covid-19 in the participating countries and was terminated in September 2020 since a date for re-starting was not foreseeable.
Other terminated trials from Fresenius Kabi
Other Critical Illness trials with similar outcome
A PHASE4 clinical study on Critical Illness, this trial is terminated or withdrawn. The trial is conducted by Fresenius Kabi and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE4
-
Apr 2020 — Sep 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fresenius Kabi
For direct contact, visit the study record on ClinicalTrials.gov .